ScienceMachine Secures $3.5 Million Pre-Seed to Advance Autonomous AI for Biotech Research

ScienceMachine, a London-based biotech AI startup, has secured $3.5 million in a pre-seed funding round to accelerate its mission of transforming biomedical research through autonomous AI. The round was led by Revent and Nucleus Capital, with participation from Juniper, Opal Ventures, and several strategic angel investors. (Tech.eu)

Founded in 2025 by Lorenzo Sani and Benjamin Tenmann, ScienceMachine aims to address the growing complexity of data in biotech and pharmaceutical research. Their flagship product, “Sam,” is an autonomous AI agent designed to automate the entire data analysis pipeline—from cleaning and structuring to analysis and visualization—without human intervention. This 24/7 AI bioinformatician enables researchers to extract insights from their data more quickly, accurately, and cost-effectively. The company claims that Sam can deliver results in hours that would typically take months, significantly accelerating the pace of scientific discovery. (EU-Startups)

Despite having a team of only two full-time employees, ScienceMachine has already attracted interest from leading biotech and pharmaceutical companies. The company’s approach has been described as one of the most impressive examples of execution, with its product delivering measurable value to customers and positioning it to disrupt one of the largest and most important markets in the world. (Tech.eu)

The funding will support ScienceMachine’s product development and expansion efforts, particularly in sales and pharmaceutical partnerships. The company plans to expand its reach from biotech startups into larger companies, where annual contract values are higher and the need for scalable, flexible data automation is even greater. (Tech.eu)

ScienceMachine’s innovative use of AI to automate complex data analysis tasks addresses a critical bottleneck in the life sciences industry. By providing researchers with powerful tools to analyze and visualize their data, the company is helping to accelerate the development of new therapies and treatments. With its strong backing and promising technology, ScienceMachine is well-positioned to become a leader in the biotech AI space.